Study of Intratumoral Selicrelumab With Atezolizumab in Patients With Refractory or Relapsed B Cell Lymphoma

Sponsor
The Lymphoma Academic Research Organisation
Study ID
NCT03892525
Phase
PHASE1
Status
Terminated

Conditions

  • Recurrent B-Cell Non-Hodgkin Lymphoma
  • Refractory B-Cell Non-Hodgkin Lymphoma

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Selicrelumab — DRUG
    escalated dose in intratumoral injection, every 3 weeks, for 3 cycles
  • Atezolizumab — DRUG
    1200mg IV every 3 week until progression or relapse for maximum 1 year

Study Details

This is a multicenter, open, dose escalation phase Ib trial of intratumoral agonistic anti-CD40 Ab (Selicrelumab intratumoral every 3 weeks for 3 cycles) in combination with anti-PDL1 Ab (Atezolizumab 1200mg intravenous every 3 weeks) in patients with refractory or relapsed B cell lymphoma

Key Dates

Start date
Jul 4, 2019
Status verified
Jul 2021
Primary completion
Apr 7, 2021
Completion
Apr 7, 2021

Study Design

Enrollment
4 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: treatment

Primary Outcome Measure

optimal dose of intratumoral Selicrelumab in combination with flat doses of Atezolizumab IV [ Time Frame: 21 days (1 cycle) ]

Related Studies